DEVELOPMENT AND CHARACTERIZATION OF NEW VACCINES EXPRESSING THE RV2626C PROTEIN TO PREVENT LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION

MORELLI, MARÍA P.; DEL MADICO ZAJAC, MP; AMIANO, N; TATEOSIAN, NANCY L.; MARTIN, CANDELA; GARCIA, VE

Congreso; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; 2021

Sociedad Argentina de Inmunologia

Almost 2 billion persons are latently infected with M ycobacterium tuberculosis (Mtb) and at risk of disease reactivation.In an in vitro Mtb latency model, Rv2626c was shown to be up-regulated during hypoxic conditions.Rv2626c is expressed by Mycobacerium tuberculosis but not by BCG.Previously, we demonstrated that Rv2626c induced IFN-γ responses in peripheral blood mononuclear cells (PBMCs) or whole blood from latent tuberculosis individuals (LTBI).Our main aim was to develop and evaluate a new candidate vaccine including a recombinant Ankara modified vaccinia virus (MVA) expressing the Rv2626c protein (MVA2626c) and the Rv2626c DNA (DNA vaccine).